The Worldwide Pulmonary Arterial Hypertension Industry is Expected to Reach $11+ Billion by 2027

DUBLIN, Jan. 21, 2022 /PRNewswire/ -- The "Global Pulmonary Arterial Hypertension (2021-2027) by Drug Class, Route of Administration, Distribution Mode, and Geography, IGR Competitive Analysis, Impact of Covid-19, Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

The Global Pulmonary Arterial Hypertension Market is estimated to be USD 8.1 Bn in 2021 and is expected to reach USD 11.68 Bn by 2027, growing at a CAGR of 6.2%.

Some of the factors that impact the growth of the global pulmonary arterial hypertension market are the change in the lifestyles, rising geriatric population, and the increasing prevalence of pulmonary arterial hypertension (PAH). Several Government and private sector initiatives such as the rare disease act and the orphan drug act that create awareness and offer incentives such as tax waivers, credits, assistance & support are expected to contribute to the growth rate of the global pulmonary arterial hypertension market.

However, discontinuing of drug production by major players during clinical trials and stringent regulations by Government, lack of awareness about the presence of pulmonary arterial hypertension among patients, and high diagnosis and treatment cost are expected to hinder the market growth. Technology advancements such as biomarker and new gene therapy for the treatment and advanced oral drugs create an opportunity for the market.

Market Dynamics

Drivers

• Growing Burden of Pulmonary Arterial Hypertension
• Government and Private Support for the Development of Orphan Drugs
• Growing Geriatric Population

Restraints

• Patent Expiration of Key Molecules
• Side Effects Associated with the Drugs
• Lack of Awareness among People in Developing Countries

Challenges

• High Costs of Diagnosis and Treatment
• Lack of Awareness
• Expiry of Patents

Opportunities

• Advance Oral Drugs for Pulmonary Arterial Hypertension
• Technology Advancements such as Biomaker and New Gene Therapy for the Treatment

The Global Pulmonary Arterial Hypertension is segmented based on Drug Class, Route of Administration, Distribution Mode, and Geography.

Global Pulmonary Arterial Hypertension Market, By Drug Class

• Introduction
• Prostacyclin and Prostacyclin Analogs
• Soluble Guanylate Cyclase (SGC) Stimulators
• Endothelin Receptor Antagonists (ERAs)
• Phosphodiesterase 5 (Pde-5)
• Calcium Channel Blockers
• Others

Global Pulmonary Arterial Hypertension Market, By Route of Administration

• Introduction
• Oral
• Injectable

Global Pulmonary Arterial Hypertension Market, By Distribution Mode

• Introduction
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Pulmonary Arterial Hypertension Market, By Geography

• Introduction
• North America
• South America
• Europe
• Asia Pacific
• The Middle East and Africa

Company Profiles

Some of the companies covered in this report are United Therapeutics Corporation, GlaxoSmithKline plc, Novartis International AG, AstraZeneca, Bayer Healthcare AG, Pfizer Inc., Gilead Sciences, Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, and Daiichi Sankyo Company Limited. and others.

Competitive Quadrant

The report includes the Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?

• The report offers a comprehensive evaluation of the Global Pulmonary Arterial Hypertension Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.

• The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
• The report includes in-depth market analysis using Porter's 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.

• The report also contains the competitive analysis using the Competitive Quadrant, the publisher's Proprietary competitive positioning tool.

Report Highlights:

• A complete analysis of the market including parent industry
• Important market dynamics and trends
• Market segmentation
• Historical, current, and projected size of the market based on value and volume
• Market shares and strategies of key players
• Recommendations to companies for strengthening their foothold in the market

Key Topics Covered:

1. Report Description

2. Research Methodology

3. Executive Summary

4. Market Overview
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Trends

5. Market Analysis
5.1 Porter's Five Forces Analysis
5.2 Impact of COVID-19
5.3 Ansoff Matrix Analysis

6. Global Pulmonary Arterial Hypertension Market, By Drug Class
6.1 Introduction
6.2 Prostacyclin and Prostacyclin Analogs
6.3 Soluble Guanylate Cyclase (Sgc) Stimulators
6.4 Endothelin Receptor Antagonists (ERAs)
6.5 Phosphodiesterase 5 (Pde-5)
6.6 Calcium Channel Blockers
6.7 Others

7. Global Pulmonary Arterial Hypertension Market, By Route of Administration
7.1 Introduction
7.2 Oral
7.3 Injectable

8. Global Pulmonary Arterial Hypertension Market, By Distribution Mode
8.1 Introduction
8.2 Hospital Pharmacy
8.3 Online Pharmacy
8.4 Retail Pharmacy

9. Global Pulmonary Arterial Hypertension Market, By Geography

10. Competitive Landscape
10.1 Competitive Quadrant
10.2 Market Share Analysis
10.3 Competitive Scenario
10.3.1 Mergers & Acquisitions
10.3.2 Agreements, Collaborations, & Partnerships
10.3.3 New Product Launches & Enhancements
10.3.4 Investments & Fundings

11. Company Profiles
11.1 Gilead Sciences, Inc.
11.2 United Therapeutics Corporation
11.3 Novartis International AG
11.4 GlaxoSmithKline Plc. (GSK)
11.5 Pfizer, Inc.
11.6 Dong-A ST Co., Ltd.
11.7 Merck Sharp & Dohme Corp.
11.8 Bayer HealthCare AG
11.9 Arena Pharmaceuticals
11.10 Actelion Pharmaceuticals Ltd
11.11 Daiichi Sankyo Company, Limited
11.12 Gilead Sciences
11.13 Johnson & Johnson
11.14 AstraZeneca
11.15 Bristol-Myers Squibb Company

12. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/7wk81s

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets